莱卡尼马布显示,它对从阿尔茨海默病大脑中分离出来的Aβ原纤维细胞具有高度选择性的结合
Malin Johannesson1, Linda Söderberg1, Olof Zachrisson1
1BioArctic AB, Warfvinges väg 35, SE-112 51 Stockholm, Sweden.
Molecular and cellular neurosciences
|June 21, 2024
概括
在阿尔茨海默病的大脑中,莱卡内马布优先向可溶性聚合性粉样β (Aβ) 原纤维,特别是Aβ42. 这种结合性概况表明治疗潜力和不良事件风险降低.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 免疫疗法需要了解抗体与粉样β (Aβ) 结合的有效性和安全性.
- 莱卡尼马布是一种IgG1抗体,向可溶性Aβ原纤维素.
研究的目的:
- 在死后AD大脑中描述Aβ形式.
- 研究lecanemab与这些Aβ形式的结合相互作用.
主要方法:
- 死亡后的脑组织提取和分离 (大小排除色谱,密度梯度超离心).
- 使用免疫试验,免疫沉 (IP) 和质谱法进行分析.
- 莱卡内马布免疫组织化学.
主要成果:
- 大多数AD大脑中的Aβ是不溶性的,Aβ42是最丰富的形式.
- 可溶性Aβ42存在于聚合的原纤维结构中,在AD患者中含量更高.
- 莱卡尼马布优先结合于Aβ42原纤维素,并且对Aβ40丰富纤维素的结合率降低.
结论:
- 莱卡尼马布向可溶性聚合Aβ42原纤维素,这是AD的一个关键治疗点.
- 观察到与Aβ斑块和神经内Aβ结合.
- 优选的结合特征可能会减少与粉样蛋白相关的成像异常相关的不良事件.
相关概念视频
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


